Jenny Morton
HealthPartners
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Jenny Morton.
Nature Genetics | 2006
Neil V. Morgan; Shawn K. Westaway; Jenny Morton; Allison Gregory; Paul Gissen; Scott Sonek; Hakan Cangul; Jason Coryell; Natalie Canham; Nardo Nardocci; Giovanna Zorzi; Shanaz Pasha; Diana Rodriguez; Isabelle Desguerre; Amar Mubaidin; Enrico Bertini; Richard C. Trembath; Alessandro Simonati; Carolyn Schanen; Colin A. Johnson; Barbara Levinson; C. Geoffrey Woods; Beth Wilmot; Patricia L. Kramer; Jane Gitschier; Eamonn R. Maher; Susan J. Hayflick
Neurodegenerative disorders with high brain iron include Parkinson disease, Alzheimer disease and several childhood genetic disorders categorized as neuroaxonal dystrophies. We mapped a locus for infantile neuroaxonal dystrophy (INAD) and neurodegeneration with brain iron accumulation (NBIA) to chromosome 22q12-q13 and identified mutations in PLA2G6, encoding a calcium-independent group VI phospholipase A2, in NBIA, INAD and the related Karak syndrome. This discovery implicates phospholipases in the pathogenesis of neurodegenerative disorders with iron dyshomeostasis.
American Journal of Human Genetics | 2007
Dagan Jenkins; Dominik Seelow; Fernanda Sarquis Jehee; Chad A. Perlyn; Luis Garcia Alonso; Daniela F. Bueno; Dian Donnai; Dragana Josifiova; Irene M.J. Mathijssen; Jenny Morton; Karen Helene Ørstavik; Elizabeth Sweeney; Steven A. Wall; Marsh Jl; Peter Nürnberg; Maria Rita Passos-Bueno; Andrew O.M. Wilkie
Carpenter syndrome is a pleiotropic disorder with autosomal recessive inheritance, the cardinal features of which include craniosynostosis, polysyndactyly, obesity, and cardiac defects. Using homozygosity mapping, we found linkage to chromosome 6p12.1-q12 and, in 15 independent families, identified five different mutations (four truncating and one missense) in RAB23, which encodes a member of the RAB guanosine triphosphatase (GTPase) family of vesicle transport proteins and acts as a negative regulator of hedgehog (HH) signaling. In 10 patients, the disease was caused by homozygosity for the same nonsense mutation, L145X, that resides on a common haplotype, indicative of a founder effect in patients of northern European descent. Surprisingly, nonsense mutations of Rab23 in open brain mice cause recessive embryonic lethality with neural-tube defects, suggesting a species difference in the requirement for RAB23 during early development. The discovery of RAB23 mutations in patients with Carpenter syndrome implicates HH signaling in cranial-suture biogenesis--an unexpected finding, given that craniosynostosis is not usually associated with mutations of other HH-pathway components--and provides a new molecular target for studies of obesity.
Nature Genetics | 2005
Irene A. Aligianis; Colin A. Johnson; Paul Gissen; Dongrong Chen; Daniel J. Hampshire; Katrin Hoffmann; Esther N Maina; Neil V. Morgan; Louise Tee; Jenny Morton; John R. Ainsworth; Denise Horn; Elisabeth Rosser; Trevor Cole; Irene Stolte-Dijkstra; Karen Fieggen; Jill Clayton-Smith; André Mégarbané; Julian Shield; Ruth Newbury-Ecob; William B. Dobyns; John M. Graham; Klaus W. Kjaer; Mette Warburg; Jacqueline Bond; Richard C. Trembath; Laura W. Harris; Yoshimi Takai; Stefan Mundlos; David Tannahill
Warburg Micro syndrome (WARBM1) is a severe autosomal recessive disorder characterized by developmental abnormalities of the eye and central nervous system and by microgenitalia. We identified homozygous inactivating mutations in RAB3GAP, encoding RAB3 GTPase activating protein, a key regulator of the Rab3 pathway implicated in exocytic release of neurotransmitters and hormones, in 12 families with Micro syndrome. We hypothesize that the underlying pathogenesis of Micro syndrome is a failure of exocytic release of ocular and neurodevelopmental trophic factors.
American Journal of Human Genetics | 2006
Neil V. Morgan; Louise Brueton; Phillip Cox; Marie T. Greally; John Tolmie; Shanaz Pasha; Irene A. Aligianis; Hans van Bokhoven; Tamas Marton; Lihadh Al-Gazali; Jenny Morton; Christine Oley; Colin A. Johnson; Richard C. Trembath; Han G. Brunner; Eamonn R. Maher
Multiple pterygium syndromes (MPSs) comprise a group of multiple-congenital-anomaly disorders characterized by webbing (pterygia) of the neck, elbows, and/or knees and joint contractures (arthrogryposis). In addition, a variety of developmental defects (e.g., vertebral anomalies) may occur. MPSs are phenotypically and genetically heterogeneous but are traditionally divided into prenatally lethal and nonlethal (Escobar) types. To elucidate the pathogenesis of MPS, we undertook a genomewide linkage scan of a large consanguineous family and mapped a locus to 2q36-37. We then identified germline-inactivating mutations in the embryonal acetylcholine receptor gamma subunit (CHRNG) in families with both lethal and nonlethal MPSs. These findings extend the role of acetylcholine receptor dysfunction in human disease and provide new insights into the pathogenesis and management of fetal akinesia syndromes.
Human Genetics | 1994
Yvonne Wallis; Fiona Macdonald; Maj A. Hultén; Jenny Morton; Carol M. McKeown; John P. Neoptolemos; Mike Keighley; Dion Morton
Mutations in the adenomatous polyposis coli (APC) gene are responsible for the disease familial adenomatous polyposis (FAP), a dominantly inherited predispostion to colorectal cancer. The most common extra-colonic manifestation is congenital hypertrophy of the retinal pigment epithelium (CHRPE), expressed in up to 90% of FAP kindreds. Chain-terminating APC mutations were characterised in 26 unrelated FAP patients. Results show that CHRPE expression is determined by the length of truncated protein product. CHRPE is therefore the first extracolonic manifestation of FAP to be shown to be under the control of the APC mutation site and should facilitate the detection of constitutional APC mutations in FAP kindreds.
American Journal of Human Genetics | 2011
Danai Bem; Shin Ichiro Yoshimura; Ricardo Nunes-Bastos; Frances F. Bond; Manju A. Kurian; Fatima Rahman; Mark T. Handley; Yavor Hadzhiev; Imran Masood; Ania Straatman-Iwanowska; Andrew R. Cullinane; Alisdair McNeill; Shanaz Pasha; Gail Kirby; Zubair Ahmed; Jenny Morton; Denise Williams; John M. Graham; William B. Dobyns; Lydie Burglen; John R. Ainsworth; Paul Gissen; Ferenc Müller; Eamonn R. Maher; Francis A. Barr; Irene A. Aligianis
Warburg Micro syndrome and Martsolf syndrome are heterogenous autosomal-recessive developmental disorders characterized by brain, eye, and endocrine abnormalities. Previously, identification of mutations in RAB3GAP1 and RAB3GAP2 in both these syndromes implicated dysregulation of the RAB3 cycle (which controls calcium-mediated exocytosis of neurotransmitters and hormones) in disease pathogenesis. RAB3GAP1 and RAB3GAP2 encode the catalytic and noncatalytic subunits of the hetrodimeric enzyme RAB3GAP (RAB3GTPase-activating protein), a key regulator of the RAB3 cycle. We performed autozygosity mapping in five consanguineous families without RAB3GAP1/2 mutations and identified loss-of-function mutations in RAB18. A c.71T > A (p.Leu24Gln) founder mutation was identified in four Pakistani families, and a homozygous exon 2 deletion (predicted to result in a frameshift) was found in the fifth family. A single family whose members were compound heterozygotes for an anti-termination mutation of the stop codon c.619T > C (p.X207QextX20) and an inframe arginine deletion c.277_279 del (p.Arg93 del) were identified after direct gene sequencing and multiplex ligation-dependent probe amplification (MLPA) of a further 58 families. Nucleotide binding assays for RAB18(Leu24Gln) and RAB18(Arg93del) showed that these mutant proteins were functionally null in that they were unable to bind guanine. The clinical features of Warburg Micro syndrome patients with RAB3GAP1 or RAB3GAP2 mutations and RAB18 mutations are indistinguishable, although the role of RAB18 in trafficking is still emerging, and it has not been linked previously to the RAB3 pathway. Knockdown of rab18 in zebrafish suggests that it might have a conserved developmental role. Our findings imply that RAB18 has a critical role in human brain and eye development and neurodegeneration.
European Journal of Human Genetics | 2012
Siddharth Banka; Ratna Veeramachaneni; William Reardon; Emma Howard; Sancha Bunstone; Nicola Ragge; Michael J. Parker; Yanick J. Crow; Bronwyn Kerr; Helen Kingston; Kay Metcalfe; Kate Chandler; Alex Magee; Fiona Stewart; Vivienne McConnell; Deirdre E. Donnelly; Siren Berland; Gunnar Houge; Jenny Morton; Christine Oley; Nicole Revencu; Soo Mi Park; Sally Davies; Andrew E. Fry; Sally Ann Lynch; Harinder Gill; Susann Schweiger; Wayne W K Lam; John Tolmie; Shehla Mohammed
MLL2 mutations are detected in 55 to 80% of patients with Kabuki syndrome (KS). In 20 to 45% patients with KS, the genetic basis remains unknown, suggesting possible genetic heterogeneity. Here, we present the largest yet reported cohort of 116 patients with KS. We identified MLL2 variants in 74 patients, of which 47 are novel and a majority are truncating. We show that pathogenic missense mutations were commonly located in exon 48. We undertook a systematic facial KS morphology study of patients with KS at our regional dysmorphology meeting. Our data suggest that nearly all patients with typical KS facial features have pathogenic MLL2 mutations, although KS can be phenotypically variable. Furthermore, we show that MLL2 mutation-positive KS patients are more likely to have feeding problems, kidney anomalies, early breast bud development, joint dislocations and palatal malformations in comparison with MLL2 mutation-negative patients. Our work expands the mutation spectrum of MLL2 that may help in better understanding of this molecule, which is important in gene expression, epigenetic control of active chromatin states, embryonic development and cancer. Our analyses of the phenotype indicates that MLL2 mutation-positive and -negative patients differ systematically, and genetic heterogeneity of KS is not as extensive as previously suggested. Moreover, phenotypic variability of KS suggests that MLL2 testing should be considered even in atypical patients.
American Journal of Human Genetics | 2006
Stephen R.F. Twigg; Kazuya Matsumoto; Alexa Kidd; Anne Goriely; Indira B. Taylor; Richard B. Fisher; A. Jeannette M. Hoogeboom; Irene M.J. Mathijssen; M. Teresa Lourenço; Jenny Morton; Elizabeth Sweeney; Louise C. Wilson; Han G. Brunner; John B. Mulliken; Steven A. Wall; Andrew O.M. Wilkie
Craniofrontonasal syndrome (CFNS) is an X-linked disorder that exhibits a paradoxical sex reversal in phenotypic severity: females characteristically have frontonasal dysplasia, craniosynostosis, and additional minor malformations, but males are usually mildly affected with hypertelorism only. Despite this, males appear underrepresented in CFNS pedigrees, with carrier males encountered infrequently compared with affected females. To investigate these unusual genetic features of CFNS, we exploited the recent discovery of causative mutations in the EFNB1 gene, which encodes ephrin-B1, to survey the molecular alterations in 59 families (39 newly investigated and 20 published elsewhere). We identified the first complete deletions of EFNB1, catalogued 27 novel intragenic mutations, and used Pyrosequencing and analysis of nearby polymorphic alleles to quantify mosaic cases and to determine the parental origin of verified germline mutations. Somatic mosaicism was demonstrated in 6 of 53 informative families, and, of 17 germline mutations in individuals for whom the parental origin of mutation could be demonstrated, 15 arose from the father. We conclude that the major factor accounting for the relative scarcity of carrier males is the bias toward mutations in the paternal germline (which present as affected female offspring) combined with reduced reproductive fitness in affected females. Postzygotic mutations also contribute to the female preponderance, whereas true nonpenetrance in males who are hemizygous for an EFNB1 mutation appears unusual. These results highlight the importance of considering possible origins of mutation in the counseling of families with CFNS and provide a generally applicable approach to the combined analysis of mosaic and germline mutations.
European Journal of Human Genetics | 2010
Kristien Hoornaert; Chantal Dewinter; Thomas Rosenberg; Frits A Beemer; Jules G. Leroy; Laila Bendix; Erik Björck; Maryse Bonduelle; Odile Boute; Valérie Cormier-Daire; Christine E.M. de Die-Smulders; Anne Dieux-Coeslier; Hélène Dollfus; Mariet W. Elting; Andrew Green; Veronica I. Guerci; Raoul C. M. Hennekam; Yvonne Hilhorts-Hofstee; Muriel Holder; Carel B. Hoyng; Kristi J. Jones; Dragana Josifova; Ilkka Kaitila; Suzanne Kjaergaard; Yolande H. Kroes; Kristina Lagerstedt; Melissa Lees; Martine LeMerrer; Cinzia Magnani; Carlo Marcelis
Stickler syndrome is an autosomal dominant connective tissue disorder caused by mutations in different collagen genes. The aim of our study was to define more precisely the phenotype and genotype of Stickler syndrome type 1 by investigating a large series of patients with a heterozygous mutation in COL2A1. In 188 probands with the clinical diagnosis of Stickler syndrome, the COL2A1 gene was analyzed by either a mutation scanning technique or bidirectional fluorescent DNA sequencing. The effect of splice site alterations was investigated by analyzing mRNA. Multiplex ligation-dependent amplification analysis was used for the detection of intragenic deletions. We identified 77 different COL2A1 mutations in 100 affected individuals. Analysis of the splice site mutations showed unusual RNA isoforms, most of which contained a premature stop codon. Vitreous anomalies and retinal detachments were found more frequently in patients with a COL2A1 mutation compared with the mutation-negative group (P<0.01). Overall, 20 of 23 sporadic patients with a COL2A1 mutation had either a cleft palate or retinal detachment with vitreous anomalies. The presence of vitreous anomalies, retinal tears or detachments, cleft palate and a positive family history were shown to be good indicators for a COL2A1 defect. In conclusion, we confirm that Stickler syndrome type 1 is predominantly caused by loss-of-function mutations in the COL2A1 gene as >90% of the mutations were predicted to result in nonsense-mediated decay. On the basis of binary regression analysis, we developed a scoring system that may be useful when evaluating patients with Stickler syndrome.
European Journal of Human Genetics | 2011
chirag patel; Lisa Cooper-Charles; Dominic McMullan; Judith Walker; Val Davison; Jenny Morton
Gilles de la Tourette syndrome is a complex neuropsychiatric disorder with a strong genetic basis. We identified a male patient with Tourette syndrome-like tics and an apparently balanced de novo translocation [46,XY,t(2;7)(p24.2;q31)]. Further analysis using array comparative genomic hybridisation (CGH) revealed a cryptic deletion at 7q31.1–7q31.2. Breakpoints disrupting this region have been reported in one isolated and one familial case of Tourette syndrome. In our case, IMMP2L, a gene coding for a human homologue of the yeast inner mitochondrial membrane peptidase subunit 2, was disrupted by the breakpoint on 7q31.1, with deletion of exons 1–3 of the gene. The IMMP2L gene has previously been proposed as a candidate gene for Tourette syndrome, and our case provides further evidence of its possible role in the pathogenesis. The deleted region (7q31.1–7q31.2) of 7.2 Mb of genomic DNA also encompasses numerous genes, including FOXP2, associated with verbal dyspraxia, and the CFTR gene.